Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, et al. (March 2003). "Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis". JAMA. 289 (12): 1537–45. doi:10.1001/jama.289.12.1470. PMID12672771.
Schier JG, Traub SJ, Hoffman RS, Nelson LS (2003). "Ephedrine-induced cardiac ischemia: exposure confirmed with a serum level". Journal of Toxicology. Clinical Toxicology. 41 (6): 849–53. doi:10.1081/clt-120025350. PMID14677795. S2CID23359388.
Palamar J (January 2011). "How ephedrine escaped regulation in the United States: a historical review of misuse and associated policy". Health Policy (Review). 99 (1): 1–9. doi:10.1016/j.healthpol.2010.07.007. PMID20685002.
Grue-Sorensen G, Spenser ID (May 1, 1988). "Biosynthesis of ephedrine". Journal of the American Chemical Society. 110 (11): 3714–3715. doi:10.1021/ja00219a086. ISSN0002-7863.
Yamasaki K, Tamaki T, Uzawa S, Sankawa U, Shibata S (1973). "Participation of C6-C1 unit in the biosynthesis of ephedrine in Ephedra". Phytochemistry. 12 (12): 2877–2882. Bibcode:1973PChem..12.2877Y. doi:10.1016/0031-9422(73)80499-6.
Ma G, Bavadekar SA, Davis YM, Lalchandani SG, Nagmani R, Schaneberg BT, et al. (July 2007). "Pharmacological effects of ephedrine alkaloids on human alpha(1)- and alpha(2)-adrenergic receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics. 322 (1): 214–221. doi:10.1124/jpet.107.120709. PMID17405867. S2CID86429875.
World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
Yamasaki K, Tamaki T, Uzawa S, Sankawa U, Shibata S (1973). "Participation of C6-C1 unit in the biosynthesis of ephedrine in Ephedra". Phytochemistry. 12 (12): 2877–2882. Bibcode:1973PChem..12.2877Y. doi:10.1016/0031-9422(73)80499-6.
Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, et al. (March 2003). "Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis". JAMA. 289 (12): 1537–45. doi:10.1001/jama.289.12.1470. PMID12672771.
Schier JG, Traub SJ, Hoffman RS, Nelson LS (2003). "Ephedrine-induced cardiac ischemia: exposure confirmed with a serum level". Journal of Toxicology. Clinical Toxicology. 41 (6): 849–53. doi:10.1081/clt-120025350. PMID14677795. S2CID23359388.
Palamar J (January 2011). "How ephedrine escaped regulation in the United States: a historical review of misuse and associated policy". Health Policy (Review). 99 (1): 1–9. doi:10.1016/j.healthpol.2010.07.007. PMID20685002.
Ma G, Bavadekar SA, Davis YM, Lalchandani SG, Nagmani R, Schaneberg BT, et al. (July 2007). "Pharmacological effects of ephedrine alkaloids on human alpha(1)- and alpha(2)-adrenergic receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics. 322 (1): 214–221. doi:10.1124/jpet.107.120709. PMID17405867. S2CID86429875.
Ma G, Bavadekar SA, Davis YM, Lalchandani SG, Nagmani R, Schaneberg BT, et al. (July 2007). "Pharmacological effects of ephedrine alkaloids on human alpha(1)- and alpha(2)-adrenergic receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics. 322 (1): 214–221. doi:10.1124/jpet.107.120709. PMID17405867. S2CID86429875.
Grue-Sorensen G, Spenser ID (May 1, 1988). "Biosynthesis of ephedrine". Journal of the American Chemical Society. 110 (11): 3714–3715. doi:10.1021/ja00219a086. ISSN0002-7863.